Procurement of 12 large varieties with volume will be implemented (list attached)

The results of the largest inter-provincial alliance's centralized procurement will soon be implemented, covering 11 provinces, 12 commonly used large varieties, and 31 pharmaceutical companies have successfully entered the market.

1.

As early as December 21, 2020, the Shaanxi Provincial Public Resources Trading Center issued an announcement announcing that the inter-provincial alliance's centralized drug procurement work has begun.

The inter-provincial alliance consists of 11 provinces (autonomous regions and corps) including Shaanxi, Hunan, Hainan, Shanxi, Guangxi, Guizhou, Gansu, Ningxia, Qinghai, Xinjiang, and Xinjiang Production and Construction Corps.

According to Cyber ​​Blue, this round of centralized harvesting is carried out for 13 varieties.

According to Meinenet data, the sales of compound amino acid (18AA) injection and gastrodin injection in the terminal of public medical institutions in China are both about 3 billion yuan, and the market scale is considerable.

In the end, a total of 31 pharmaceutical companies were successfully selected.

2.

According to the notice, there are 28 companies that need to confirm the supply area, including Sichuan Kelun, North China Pharmaceutical, Lepu Pharmaceutical, Harbin Sanlian, Jiangsu Hengrui, and Yuanda Pharmaceutical.

In addition, according to the provisions of the inter-provincial alliance drug centralized procurement document, the agreed procurement volume for the first year of centralized procurement jointly carried out by 11 provinces is determined according to the following rules:

If the actual selected company is one, the agreed purchase amount shall be 50% of the calculation base of the first year's agreed purchase volume; if the actual selected company is 2, the agreed purchase amount shall be 60% of the calculation base of the first year's agreed purchase amount; the actual selected company shall be 3 , The agreed purchase amount shall be 70% of the calculation base of the agreed purchase amount in the first year.

According to Cyberlan's analysis of the first year's agreed purchase volume of each province and each purchase product, the purchase volume of 11 products in Shaanxi ranks the most in 11 provinces (regions, corps), including compound amino acid (18AA) injection (500ml: 25g), Papaverine injections, tropisetron injections, etc.

The centralized procurement document stipulates that a product specification can be selected from at most three pharmaceutical companies.

(Unit: 10,000 pieces/10,000 bags/10,000 pieces)

According to the regulations, the selected companies shall alternately confirm the supply areas according to the declared quotation from low to high (when the price is the same, the technical standard score is determined first).

It is worth noting that the procurement rules of the 11 inter-provincial alliances stipulate that if the quotation of the product to be selected is ≥ 1.

Specifically, Wuhan Daan Pharmaceutical's alanyl glutamine injection (100ml: 20g), China Resources Shuanghe Limin Pharmaceutical (Jinan)'s gastrodin injection (2ml: 0.
2g), (1ml: 0.
1g) Under this mechanism, Hengrui’s papaverine hydrochloride injection and other drugs have all reported the lowest prices in the same group.

In addition to the centralized procurement alliance of 11 provinces, the "six provinces and two regions" inter-provincial alliance, the joint procurement of medicines in Beijing-Tianjin-Hebei, and the large-scale procurement alliance of Jiangsu, Zhejiang, Shanghai and Anhui provinces and one city in the Yangtze River Delta have also attracted the attention of the industry.

3.
500 varieties, the provincial centralized procurement continues to advance

Recently, the National Medical Insurance Bureau released the 2020 medical security business development statistics bulletin, showing that in 2020, provinces will generally carry out centralized procurement of medicines and medical consumables in an independent or alliance manner, involving 229 kinds of medicines and 19 types of medical consumables.

In 2020, the total amount of online procurement orders nationwide through the provincial centralized drug procurement platform is estimated to be 931.
2 billion yuan, a decrease of 60.
1 billion yuan from 2019.

Among them, western medicine (chemical drugs and biological products) was 752.
1 billion yuan, and Chinese patent medicine was 179.
1 billion yuan, a decrease of 59.
4 billion yuan and 700 million yuan respectively from 2019.
The drugs in the medical insurance catalog accounted for 86.
5% of the total online procurement orders, and the amount was 805.
2 billion yuan.

Recently, Hu Jinglin, director of the National Medical Insurance Administration, published an article "Promoting the High-Quality Development of Medical Security" and proposed to promote the institutionalization and normalization of centralized drug procurement and to explore the reform of the centralized procurement system for high-value medical consumables.
Improve the incentive mechanism and promote the implementation of policies for centralized procurement of medicines and medical consumables by medical institutions.
Standardize the transaction rules of the provincial-level pharmaceutical centralized procurement platform, and accelerate the establishment and implementation of the pharmaceutical price and recruitment credit evaluation system.

In general, up to now, the drug price reduction effect of the national organization of centralized drug procurement, inter-provincial alliances, and provincial procurement is obvious.

According to the statistics of Medical Rubik's Cube, among the current provincial centralized procurement, chemical drugs are the mainstream of centralized procurement, biological products and traditional Chinese medicine account for a relatively small proportion, injections are the main dosage form, and antibiotics account for the highest proportion.
From the perspective of the varieties collected in various provinces, the degree of overlap between provinces is not high, and 75% of the varieties are not duplicated between provinces, which is consistent with the goal of each province to fully explore and purchase different varieties.

In addition, the provinces and inter-provincial alliances are basically divided into different quality levels and no quality levels in the setting of centralized procurement rules; they value price reduction and multi-index comprehensive scoring, and they are matched with each other.

A few days ago, the relevant departments held a centralized procurement meeting to once again clarify that the provincial-level volume procurement in 2021 will continue to be promoted with a catalog of 500 varieties, combined with the national procurement and over-evaluation of specific varieties.

According to previous news, in July 2020, the industry circulated the content of the National Centralized Procurement Conference: The National Medical Insurance Bureau requires that the top 80% of the medicines be ranked according to the purchase amount, covering about 500 drugs, and each locality can determine the number according to the specific situation.
Specifically, it will cover 250 in 2021, and full coverage in 2022.
Those that are not carried out by the state will be organized by provinces.

It can be said that, relying on more subjects, provincial and inter-provincial centralized procurement of more varieties will continue.

Attachment: Results of the selection in the centralized procurement of the 11 provincial alliances